Other languages KALA BIO, Inc.

Equities

KALA

US4831192020

Market Closed - Nasdaq Other stock markets 02:00:01 04/05/2024 am IST			5-day change	1st Jan Change
7.007 ^USD	+3.74%		+11.23%	+0.11%

02/04	HC Wainwright Trims KALA BIO's Price Target to $21 From $22, Keeps Buy Rating	MT
29/03	KALA BIO, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

KALA BIO, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/03
KALA BIO, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	29/03
KALA BIO, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11
KALA BIO, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	04/23/04
Kala Pharmaceuticals Changes Name to Kala Bio	03/23/03
Kala Pharmaceuticals, Inc. Announces Robert Paull Not Stands for Re-Election as A Director	12/23/12
Kala Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	09/23/09
Kala Pharmaceuticals Unit Secures $15 Million Grant from California Institute for Regenerative Medicine	28/23/28
Kala Pharmaceuticals, Inc. Appoints Francis Mah as Chief Medical Advisor	29/23/29
Kala Pharmaceutical to Proceed with Corneal Epithelial Defect Trial After Positive Safety Data in Cohort 1	27/23/27
Kala Pharmaceuticals, Inc. Announces Positive Safety Update from Cohort 1 of Chase Phase 2B Clinical Trial Evaluating KPI-012 in Patients with PCED	27/23/27
Kala Pharmaceuticals Files $350 Million Mixed Shelf, Files Shelf on Behalf of Selling Stockholders	06/23/06
Kala Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	03/23/03
Kala Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	03/23/03
Top Midday Gainers	31/22/31
Sector Update: Stocks Dragged Lower with Broader Friday Markets	31/22/31
Fed's Fight Against Inflation Set to Make 2022 Worst Year Since Financial Crisis for US Equities	31/22/31
S&P 500 On Course Toward Worst Year Since Financial Crisis	30/22/30
Nasdaq, S&P 500 Poised to End 2022 as Worst Year Since Financial Crisis	30/22/30
Top Premarket Gainers	30/22/30

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages KALA BIO, Inc.

Equities

KALA

US4831192020

Other languages

Filters